145 related articles for article (PubMed ID: 15528325)
1. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation.
Stumbles PA; Himbeck R; Frelinger JA; Collins EJ; Lake RA; Robinson BW
J Immunol; 2004 Nov; 173(10):5923-8. PubMed ID: 15528325
[TBL] [Abstract][Full Text] [Related]
2. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL.
Nelson DJ; Mukherjee S; Bundell C; Fisher S; van Hagen D; Robinson B
J Immunol; 2001 May; 166(9):5557-66. PubMed ID: 11313395
[TBL] [Abstract][Full Text] [Related]
3. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity.
Marzo AL; Kinnear BF; Lake RA; Frelinger JJ; Collins EJ; Robinson BW; Scott B
J Immunol; 2000 Dec; 165(11):6047-55. PubMed ID: 11086036
[TBL] [Abstract][Full Text] [Related]
5. Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction.
Boonman ZF; van Mierlo GJ; Fransen MF; Franken KL; Offringa R; Melief CJ; Jager MJ; Toes RE
J Immunol; 2004 Feb; 172(3):1567-74. PubMed ID: 14734736
[TBL] [Abstract][Full Text] [Related]
6. CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-gamma-producing T cells from tumor-infiltrating lymphocytes.
Terheyden P; Straten P; Bröcker EB; Kämpgen E; Becker JC
J Immunol; 2000 Jun; 164(12):6633-9. PubMed ID: 10843723
[TBL] [Abstract][Full Text] [Related]
7. CD40-activated B cells contribute to mesothelioma tumor regression.
Jackaman C; Cornwall S; Graham PT; Nelson DJ
Immunol Cell Biol; 2011 Feb; 89(2):255-67. PubMed ID: 20628372
[TBL] [Abstract][Full Text] [Related]
8. Tumor antigens are constitutively presented in the draining lymph nodes.
Marzo AL; Lake RA; Lo D; Sherman L; McWilliam A; Nelson D; Robinson BW; Scott B
J Immunol; 1999 May; 162(10):5838-45. PubMed ID: 10229818
[TBL] [Abstract][Full Text] [Related]
9. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
[TBL] [Abstract][Full Text] [Related]
10. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1.
Coles RM; Mueller SN; Heath WR; Carbone FR; Brooks AG
J Immunol; 2002 Jan; 168(2):834-8. PubMed ID: 11777979
[TBL] [Abstract][Full Text] [Related]
11. Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain.
Calzascia T; Di Berardino-Besson W; Wilmotte R; Masson F; de Tribolet N; Dietrich PY; Walker PR
J Immunol; 2003 Sep; 171(5):2187-91. PubMed ID: 12928361
[TBL] [Abstract][Full Text] [Related]
12. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice.
Staveley-O'Carroll K; Schell TD; Jimenez M; Mylin LM; Tevethia MJ; Schoenberger SP; Tevethia SS
J Immunol; 2003 Jul; 171(2):697-707. PubMed ID: 12847236
[TBL] [Abstract][Full Text] [Related]
13. In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes.
Nelson D; Bundell C; Robinson B
J Immunol; 2000 Dec; 165(11):6123-32. PubMed ID: 11086045
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
Jackaman C; Nelson DJ
Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
[TBL] [Abstract][Full Text] [Related]
15. Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes.
Oizumi S; Strbo N; Pahwa S; Deyev V; Podack ER
J Immunol; 2007 Aug; 179(4):2310-7. PubMed ID: 17675492
[TBL] [Abstract][Full Text] [Related]
16. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.
Nowak AK; Lake RA; Marzo AL; Scott B; Heath WR; Collins EJ; Frelinger JA; Robinson BW
J Immunol; 2003 May; 170(10):4905-13. PubMed ID: 12734333
[TBL] [Abstract][Full Text] [Related]
17. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells.
Lefrançois L; Altman JD; Williams K; Olson S
J Immunol; 2000 Jan; 164(2):725-32. PubMed ID: 10623816
[TBL] [Abstract][Full Text] [Related]
18. The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA.
Chan K; Lee DJ; Schubert A; Tang CM; Crain B; Schoenberger SP; Corr M
J Immunol; 2001 Mar; 166(5):3061-6. PubMed ID: 11207256
[TBL] [Abstract][Full Text] [Related]
19. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
Lynch DH; Daynes RA; Hodes RJ
J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
[TBL] [Abstract][Full Text] [Related]
20. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
